Literature DB >> 33449950

Palmitate induces fat accumulation via repressing FoxO1-mediated ATGL-dependent lipolysis in HepG2 hepatocytes.

Naiqian Zhao1, Huiwen Tan2, Li Wang1, Le Han1, Yanli Cheng1, Ying Feng1, Ting Li1, Xiaoling Liu1.   

Abstract

Obesity is closely associated with non-alcoholic fatty liver disease (NAFLD), and elevated serum palmitate is the link between obesity and excessive hepatic lipid accumulation. Forkhead box O-1 (FoxO1) is one of the FoxO family members of transcription factors and can stimulate adipose triglyceride lipase (ATGL) and suppress its inhibitor G0/G1 switch gene 2 (G0S2) expression in the liver. However, previous researches have also shown conflicting results regarding the role of FoxO1 in hepatic lipid accumulation. We therefore examined the role of FoxO1 as a downstream suppressor to palmitate-stimulated hepatic steatosis. Palmitate significantly promoted lipid accumulation but inhibited lipid decomposition in human HepG2 hepatoma cells. Palmitate also significantly reduced FoxO1, ATGL and its activator comparative gene identification-58 (CGI-58) expression but increased peroxisome proliferator-activated receptorγ (PPARγ) and its target gene G0S2 expression. FoxO1 overexpression significantly increased palmitate-inhibited ATGL and CGI-58 expression but reduced palmitate-stimulated PPARγ and its target gene G0S2 expression. FoxO1 overexpression also inhibited lipid accumulation and promoted lipolysis in palmitate-treated hepatocytes. Overall, these results indicate that FoxO1-mediated ATGL-dependent lipolysis may be an effective molecular mechanism in protecting hepatocytes from palmitate-induced fat accumulation.

Entities:  

Year:  2021        PMID: 33449950      PMCID: PMC7810308          DOI: 10.1371/journal.pone.0243938

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  38 in total

Review 1.  FoxO1, the transcriptional chief of staff of energy metabolism.

Authors:  Stavroula Kousteni
Journal:  Bone       Date:  2011-07-28       Impact factor: 4.398

Review 2.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 3.  Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models.

Authors:  Zhiyong Cheng; Morris F White
Journal:  Antioxid Redox Signal       Date:  2010-09-16       Impact factor: 8.401

4.  Macrophage CGI-58 deficiency promotes IL-1β transcription by activating the SOCS3-FOXO1 pathway.

Authors:  Hongming Miao; Juanjuan Ou; Xuan Zhang; Yujuan Chen; Bingzhong Xue; Hang Shi; Lixia Gan; Liqing Yu; Houjie Liang
Journal:  Clin Sci (Lond)       Date:  2015-04       Impact factor: 6.124

5.  CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice.

Authors:  Jill M Schroeder-Gloeckler; Shaikh Mizanoor Rahman; Rachel C Janssen; Liping Qiao; Jianhua Shao; Michael Roper; Stephanie J Fischer; Erin Lowe; David J Orlicky; James L McManaman; Carol Palmer; William L Gitomer; Wan Huang; Robert M O'Doherty; Thomas C Becker; Dwight J Klemm; Dalan R Jensen; Leslie K Pulawa; Robert H Eckel; Jacob E Friedman
Journal:  J Biol Chem       Date:  2007-03-26       Impact factor: 5.157

6.  Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism.

Authors:  Michihiro Matsumoto; Seongah Han; Tadahiro Kitamura; Domenico Accili
Journal:  J Clin Invest       Date:  2006-08-10       Impact factor: 14.808

7.  Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice.

Authors:  Naoya Yahagi; Hitoshi Shimano; Alyssa H Hasty; Takashi Matsuzaka; Tomohiro Ide; Tomohiro Yoshikawa; Michiyo Amemiya-Kudo; Sachiko Tomita; Hiroaki Okazaki; Yoshiaki Tamura; Yoko Iizuka; Ken Ohashi; Jun-Ichi Osuga; Kenji Harada; Takanari Gotoda; Ryozo Nagai; Shun Ishibashi; Nobuhiro Yamada
Journal:  J Biol Chem       Date:  2002-03-28       Impact factor: 5.157

8.  FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity.

Authors:  Michal Armoni; Chava Harel; Shiri Karni; Hui Chen; Fabiana Bar-Yoseph; Marel R Ver; Michael J Quon; Eddy Karnieli
Journal:  J Biol Chem       Date:  2006-05-02       Impact factor: 5.157

9.  FoxO1 controls insulin-dependent adipose triglyceride lipase (ATGL) expression and lipolysis in adipocytes.

Authors:  Partha Chakrabarti; Konstantin V Kandror
Journal:  J Biol Chem       Date:  2009-03-17       Impact factor: 5.157

Review 10.  Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease.

Authors:  Samir Parekh; Frank A Anania
Journal:  Gastroenterology       Date:  2007-05       Impact factor: 22.682

View more
  1 in total

Review 1.  The multifaceted roles of ER and Golgi in metabolic cardiomyopathy.

Authors:  Rida Raja; Oveena Fonseka; Haresh Ganenthiran; Wei Liu
Journal:  Front Cardiovasc Med       Date:  2022-09-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.